A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50+
SponsorInnovent Biologics Technology Limited (Shanghai R&D Center)
About this trial
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Eligibility criteria
Qualifiers
Have signed an informed consent form before participating in the research.
Male or female individuals aged 50 or above at the time of signing the informed consent form;
Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).
Disqualifiers
According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the interpretation of the study results;
The study eye has uncontrollable glaucoma;
There is an active intraocular or periocular infection or inflammation in either eye;
The non-study eye has severe visual function disorders;
Trial design
Treatments tested in this trial
- IBI302 8mg dose
Treatment groups
800 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov